INTRODUCTION
Emergence of drug resistance during the course of tuberculosis (TB) treatment and especially development of multi-drug resistant (MDR) TB is a major health hazard in many countries worldwide and is considered as an obstacle against TB control (1) .
MDR-TB is caused by a Mycobacterium tuberculosis
strain which is at least resistant to isoniazid and rifampin and usually occurs as the result of incomplete or inadequate treatment (2) . Annually, about 425,000 new MDR-TB cases occur in the world which constitutes about 5% of overall global TB burden (2) . Its prevalence worldwide is approximately 2 to 3 times this number (3) .
Diagnosis of MDR-TB requires an equipped laboratory
which is not available in many parts of the world.
Treatment of MDR-TB takes roughly 20 months; whereas, treatment of drug-susceptible TB takes 6-9 months (4).
Furthermore, second line medications used for treatment of MDR-TB have greater side effects and are more costly.
Treatment of MDR-TB is approximately 100 to 300 times more expensive than drug sensitive TB (5, 6) . Also, treatment success rate for MDR-TB is lower and it is associated with higher rates of morbidity and mortality compared to drug sensitive TB (4) .
Treatment success rate for meticulously designed MDR-TB treatment protocols with low prevalence of HIV is often in the range of 70-80% while this rate is about 90% for drug sensitive TB (7, 8) . However, treatment of patients with MDR-TB is necessary to prevent its dissemination. About 70% of patients will recover with the current treatment protocol (8) 
In which patients drug susceptibility testing (DST)
has to be performed?
Ideally, drug susceptibility testing had better be performed for all pulmonary TB patients. However, in situations where necessary equipments are not available 
TREATMENT

A. Classification of anti-TB drugs
Anti-TB medications used for treatment of MDR-TB are categorized into 5 major groups (10). Treatment regimen: In order for a regimen to be efficacious, 4 effective drugs should be included in that regimen. These drugs are selected based on drug susceptibility testing and history of drug intake by the patient (9, 13) . In Iran, considering the limited availability of second line agents and not having a routine access to drug susceptibility testing for the second line drugs, a standard regimen is used for treatment of MDR-TB patients which includes levofloxacin or ofloxacin + amikacin +cycloserine + prothionamide + ethambutol +pyrazinamide (8, 14) .
Drug dosages are presented in Table 1 . Important points:
1. Some anti-TB first line agents may be added to the standard above-mentioned regimen if proven susceptible in drug susceptibility testing (4) 2. If any of the drugs in the above-mentioned regimen cannot be administered for some reason, a fifth-group medication will be added to the regimen (4).
3. In cases where drug susceptibility testing indicates resistance to second line agents or if the patient has extensive bilateral pulmonary involvement, more than 4 drugs will be included in the regimen (4)(at present, co-amoxiclav and clarithromycin are the drugs that will be added to the regimen)
4. Treatment of extra-pulmonary MDR-TB is similar to that of pulmonary TB (15).
In all patients that use cycloserine, concomitant administration of vitamin B6 is necessary to prevent neural complications (4).
How long should the administration of injectable anti-TB agents continue?
Injectable anti-TB agents should at least continue for 8 months and preferably an additional 4 months after the sputum smear becomes negative (4, 11) . For cases with insufficient number of effective medications in their drug regimen or those with extensive bilateral pulmonary involvement, treatment with amikacin may be extended for longer periods of time (4).
Duration of Treatment:
Treatment course should continue for 20 months and at least 18 months after the sputum smear becomes negative (4, 11) . Figure 1 summarizes the phases of treatment.
Surgical treatment:
The 1: In case of susceptibility, ethambutol and pyrazinamide are also added to the regimen.
2: Amikacin needs to be continued for at least 8 months after its initiation (it had better be continued until at least 4 months after the negativity of sputum smear)
3: Sputum smear is considered negative in case of presence of two negative smears with at least a 30 day interval. Thus, all these patients have to be referred to the National Referral Center before any therapeutic intervention.
Currently, the XDR-TB treatment regimen in Iran is as follows:
Levofloxacin + Capreomycin +PAS +Prothionamide +
Co-amoxiclav + Clofazimine +Linezolid or Imipenem
In XDR-TB drug regimen, the injectable drug must be continued for at least 12 months and throughout the entire treatment course if possible.
Pretreatment assessment of patients
In addition to taking a history and performing a full clinical examination, the following conditions should be specifically asked from the patient: diabetes, renal insufficiency, acute or chronic liver disease, thyroid disease, mental illness, alcohol consumption or substance abuse, HIV and pregnancy (4).
Assessment of patients during the course of treatment:
The clinical symptoms usually disappear during the first months of treatment. Radiographic changes are mostly delayed. Thus, chest X-ray has to be repeated every 6 months unless the patient requires surgical intervention or patient's general status changes. The most important sign of recovery is the negativity of sputum smear and culture.
Between these two, culture has a greater sensitivity and must be necessarily performed (4) .
Sputum smear and culture should be repeated monthly until they become negative (twice with a 30 day interval). After negativity, sputum smear needs to be repeated monthly and sputum culture every two months (Tables 2-5 ).
Assessment of drug side effects during the treatment:
The In order to prevent neurologic complications of cycloserine, administration of vitamin B6 is essential. The recommended dosage is 50 mg vitamin B6 for each 250 mg of cycloserine administered (4). Table 2 . Important points regarding the assessment of patients during treatment:
The incidence of various adverse effects of MDR-TB treatment is demonstrated in
1. The patients have to be visited by the physician in charge of their MDR-TB treatment monthly at first until negativity and every 6 months after that.
DOTS must better be implemented for drug
consumption by the patients during the course of treatment.
3. Sputum smear and culture must be done monthly until negativity and after that sputum smear must be done monthly and sputum culture every two months.
Patients must receive daily injections.
5. Chest X-ray must be obtained at first and then every 6 months. In patients requiring surgery or those with a worsening respiratory status, chest X-ray may be obtained at any time.
6. Serum creatinine level should be monitored at first and then monthly (until using amikacin). In high risk patients, HIV positives or diabetics it better be checked every 1-3 weeks.
7. Serum potassium concentration should be monitored monthly until using Amikacin. In HIV positives, diabetics or other high risk patients it should be measured every 1-3 weeks.
8. In case of using pyrazinamide, liver tests should be ordered every 1-3 months. In HIV positives monthly testing is recommend.
9. All patients have to be evaluated and tested for concomitant HIV infection.
In HIV positive patients that use zidovudine, CBC test
should be performed monthly at first and then whenever indicated based on symptoms.
11. In patients that receive antiretroviral medications, if symptoms appear, evaluation for lactic acidosis is recommended (23, 24) .
Management of adverse effects:
Many complications during the treatment course of MDR-TB are transient. The physician needs to talk to the patient and explain that the complication is not dangerous and will be resolved and there is no need to discontinue the drugs or reduce their dosage. Considering the fact that treatment of MDR-TB in our country is according to the standard protocol, discontinuation of drugs because of related complications makes the treatment regimen incomplete and will adversely affect the outcome. Thus, in case of appearance of drug-related adverse effects, it is necessary to consult with MDR-TB specialists regarding the continuation or discontinuation of drugs. In patients with severe involvement injectable agents have to be administered for a longer period of time (6 months)
R and Z (±S)
H,E, Fluroquinolone plus an injectable agent for at least the first
2-3 months 18 months
In patients with severe involvement injectable agents have to be administered for a longer period of time (6 months)
H,E,Z (±S)
R, Fluroquinolone, plus and oral second line agent plus anijectable agemls 2-3 months 18 months
In patients with severe involvement injectable agents have to be administered for a longer period of time (6 months) b high-Dose isoniazid is defined as 16-20 mg/kg/ day. Some experts feel that high-dose isoniazid can still be used in the presence of resistance to low concentrations of isoniazid (>1% of bacilli resistant to 0.2 µg/ml but susceptible to 1 µg/ml of ispniazid), whereas isoniazid is not recommended for hugh-dose resitance (>1% of bacilli resistant to 1 µg/ml of isoniazid).
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Principles Comments
1. Use at least 4 drugs certain to be effective The more of the following factors are present, the more likely it is that the drug will be effective: 10-Nephrotoxicity: It is a side effect of injectable drugs (aminoglycosides). In case of occurrence, the responsible drugs have to be discontinued and dosage of other medications must be modified based on the serum level of creatinine (23, 24) . If the patient is stable, aminoglycosides may be initiated 2 to 3 times a week.
11-Hypokalemia and hypomagnesaemia: If the potassium serum concentration is low, magnesium serum level also needs to be checked. If serum levels of electrolytes are low, they have to be replaced (23, 24) .
12-Arthralgia: It is a side effect of quinolones which is usually resolved by the continuation of treatment. If this complication continues, pain relievers may be prescribed (23, 24) .
